Aquestive Therapeutics (AQST) continues to be on my watchlist, but it appears it might be time to pull the trigger on a buy in the near future. The company has made significant progress throughout its pipeline programs in the past few months. Most significantly, the company reported positive topline data from the crossover study for Libervant, which is the company's leading product candidate. Now that the company has a strong case for approval, they are looking to submit their NDA filing for Libervant before year-end. What is more, the company has a November